Pharmaceuticals & Biologics
Yale researchers have identified that the acute inflammatory response to biomaterials can be limited by inhibition of inflammasome-related pathways.
Mice that overexpress TGF-β have identified several novel targets (including β1 integrin) for therapeutic interventions in fibrotic lung diseases. Semaphorin 7A inhibition is also effective as a therapeutic treatment for fibrotic disease.
Yale researchers created an inactivated version of the thyphoid toxin, which can serve as the basis for the development of novel second-generation vaccines to treat typhoid fever.
GFB-204 is a novel compound that binds PDGF and VEGF and prevents binding to their respective receptors, and subsequently suppresses downstream signaling pathways.
Scientists at Yale have successfully demonstrated therapeutic efficacy of a monoclonal antibody targeting CCR5 in an animal model for Chronic Obstructive Pulmonary Disease (COPD).
Researchers at Yale have discovered a new indication for a clinical stage, cell penetrating antibody that can enhance the therapeutic effect of radiation therapy or DNA-damaging chemotherapy agents. This antibody treatment can increase tumor cell sensitivity to either radiation therapy or chemotherapy by more than 60%, and may result in a decreased amount of cancer therapy needed to kill cells and reduce the resulting toxic side effects. The antibody is also effective, by itself, against BRCA-deficient cancer cells.
A collaborative research effort, performed in part with Yale, has identified a unique method to induce the formation of new bone in targeted skeletal sites, as well as accelerate and secure the repair process of fractures.